Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics' partner Akeso announced their bispecific antibody, ivonescimab, met the overall survival (OS) endpoint in the Phase 3 HARMONi-A study for EGFR-mutated NSCLC, demonstrating a statistically significant and clinically meaningful benefit. This OS win is particularly notable as it surpasses Merck's Keytruda, which failed to show an OS benefit, and validates earlier progression-free survival data. Consequently, HC Wainwright raised Summit's price target to $50 from $44, citing 85% approval odds, and suggests SMMT could emerge as a compelling acquisition target, despite the stock trading down 7.80% at publication.

Analysis

Summit Therapeutics (SMMT) and partner Akeso have achieved a significant clinical milestone with their PD-1xVEGF bispecific antibody, ivonescimab. The drug met its primary endpoint in the Phase 3 HARMONi-A study, demonstrating a 'statistically significant and clinically meaningful' overall survival (OS) benefit for patients with EGFR-mutated non-small cell lung cancer (NSCLC). This OS win is a critical differentiating factor, especially as it positions ivonescimab favorably against Merck’s (MRK) blockbuster Keytruda, which failed to show an OS benefit in a similar setting. The positive OS data reinforces earlier findings from the HARMONi program, which showed a superior progression-free survival rate with a hazard ratio of 0.52. Citing these strong results, HC Wainwright has raised its price target on SMMT to $50 from $44 and increased the probability of approval to 85%, suggesting ivonescimab could challenge Keytruda's $30 billion franchise. The analyst note also posits that SMMT could become a compelling acquisition target. Despite this positive fundamental news, SMMT's stock experienced a 7.80% decline to $24.88, indicating a potential market disconnect from the drug's clinical and commercial prospects.

Key Decisions for Investors

• Investors should evaluate the significant disconnect between the positive Phase 3 overall survival data and the analyst's $50 price target versus the stock's recent decline, which may present a valuation opportunity.
• Consider the long-term thesis that ivonescimab's demonstrated overall survival benefit, a key advantage over Merck's Keytruda, could enable significant market share capture in the lucrative NSCLC treatment landscape.
• Monitor for developments related to M&A, as the analyst note identifies Summit as a compelling acquisition target for global pharmaceutical companies needing to secure a next-generation PD-1xVEGF bispecific antibody.
• Watch for the detailed HARMONi-A study results to be presented at an upcoming medical conference, as this will provide deeper insights into the drug's competitive profile and could serve as a near-term catalyst.